IL1B and COVID-19: The use of another inhibitor of IL-1β in severe COVID-19 patients, such as canakinumab, (n = 227; intravenously injected 450 mg for body weight of < 60 kg, 600 mg for 60–80 kg, and 750 mg for > 80 kg) did not reduce mortality or the need of invasive mechanical ventilation compared to the placebo group (n = 227) [210].